What to Expect After Your First Dose of Zepbound: Hour-by-Hour and Day-by-Day

Key Takeaways

• The first Zepbound dose is 2.5 mg, a starter dose meant to introduce your body to tirzepatide. It is not a therapeutic weight-loss dose for most patients (Lilly Zepbound prescribing information, 2024).
• Appetite suppression usually starts within 12 to 48 hours and peaks around day 3 to 5 after injection.
• Most side effects (nausea, fatigue, mild constipation, headache) appear in the first 72 hours and fade by day 7 to 10.
• Expect minimal scale movement in the first 4 weeks. The 2.5 mg dose averages 1 to 3 lb of weight loss per the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022).
• Stay hydrated (80+ oz water daily), eat protein-forward small meals, and don't push through severe nausea. The titration plan is designed to give your body 4 weeks at each dose.

Direct answer (40-60 words)

After your first 2.5 mg Zepbound injection, expect appetite suppression within 12 to 48 hours, peaking around day 3 to 5. Mild nausea, fatigue, and constipation are common in the first 72 hours and usually fade by day 10. Weight loss is minimal at the starter dose: 1 to 3 pounds over the first 4 weeks is typical.

Table of contents

1. The 30-second answer
2. The first 24 hours: hour-by-hour timeline
3. Days 2 through 7: appetite, side effects, and what's normal
4. Week 2 through week 4: settling in at 2.5 mg
5. What weight loss to expect at the starter dose
6. The most common side effects in the first month, ranked
7. What to eat and drink during the first week
8. Red flags that mean call your provider
9. When you escalate to 5 mg: what changes
10. Compounded tirzepatide vs Zepbound: any first-dose differences?
11. FAQ
12. Sources
13. Footer disclaimers

The first 24 hours: hour-by-hour timeline

Tirzepatide is absorbed gradually from the subcutaneous injection site. Plasma concentrations rise over 24 to 72 hours and peak around hour 48. Most of what you feel in the first day is anticipation, not pharmacology.

Hour 0 to 4. You probably feel nothing different. Tirzepatide hasn't reached therapeutic plasma levels yet. The injection site may have a small red dot or mild itching that resolves within an hour.

Hour 4 to 8. Some patients report a slight loss of appetite or "fullness" sensation. This is usually psychological more than pharmacological at this stage. A small percentage of patients report mild headache or fatigue, again partly nocebo.

Hour 8 to 24. Plasma tirzepatide is rising. Appetite suppression becomes real for most patients toward the end of this window. Dinner the evening of the injection often goes uneaten halfway through. Mild nausea may appear for a subset of patients, usually mild enough to ignore.

The injection site itself is rarely a problem. About 8% of patients in SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported any injection-site reaction, and most were mild and transient. A pea-sized lump or mild redness for 24 to 48 hours is normal. Pain that radiates, expanding redness, or warmth that worsens after 24 hours is not normal and warrants attention.

Days 2 through 7: appetite, side effects, and what's normal

This is the window when most patients feel the drug.

Day 2. Plasma tirzepatide approaches peak. Appetite suppression is noticeable for most patients. Many describe it as "I forgot to eat lunch." Breakfast may be smaller, lunch may be skipped, dinner may be a third of the usual portion. Energy is generally normal. Mild nausea (the kind that resolves with a cracker or ginger tea) is the most common complaint.

Day 3 to 4. Plasma tirzepatide peaks. This is when appetite suppression is strongest and when side effects, if any, are most noticeable. About 12 to 14% of patients report nausea bothersome enough to mention to a provider. Roughly 5 to 8% report mild fatigue. Constipation appears in 6 to 9% of patients, mostly in those who don't increase fluid intake to match the slowed gastric emptying.

Day 5 to 7. Plasma levels begin gradually declining. The half-life of tirzepatide is about 5 days, so you don't fall off a cliff. Side effects start to fade. Appetite suppression remains strong but less dramatic. Some patients describe day 5 to 7 as "the new normal," where eating less feels effortless rather than forced.

A few specifics that don't get talked about enough:

• Energy. Most patients feel normal energy on day 1 and day 2, slight fatigue on day 3 to 4, then normal again. The fatigue is usually mild and corresponds to lower calorie intake plus mild dehydration.
• Sleep. Some patients sleep more deeply on days 2 to 4, possibly because slower gastric emptying means lighter dinners and less reflux.
• Mood. Slight irritability is reported by a minority of patients in the first 5 days, usually attributed to caloric drop rather than the drug itself. The drug doesn't appear to alter mood directly in clinical trials.
• Bowel habits. Constipation is more common than diarrhea at the 2.5 mg dose. Higher doses tip the balance toward diarrhea for some patients.

Week 2 through week 4: settling in at 2.5 mg

By week 2, your body has adjusted to the 2.5 mg dose. Plasma levels are oscillating in a narrow steady-state range as you take your second, third, and fourth doses, one per week.

Week 2. Side effects are usually minimal. Patients report a few hours of mild nausea on injection day for some, and routine eating habits the rest of the week. Most report a measurable but small drop in hunger.

Week 3. This is often the easiest week of the starter month. Side effects have largely resolved. Eating habits are settled at a reduced level. Many patients report they are "noticeably full" after smaller portions and feel satisfied for longer between meals.

Week 4. The end of the starter month. The 2.5 mg dose is meant to be a brief introduction, not a long-term therapeutic dose. Most providers schedule a check-in at week 4 to confirm tolerability before escalating to 5 mg. If you've handled 2.5 mg without significant side effects, escalation is the standard next step.

The 2.5 mg dose itself doesn't deliver much weight loss for most patients. Per the Zepbound prescribing information, 2.5 mg is below the lowest dose tested for efficacy in obesity (5 mg). The intent is mechanical: give your body 4 weeks of exposure to tirzepatide so the higher doses produce less side-effect burden.

What weight loss to expect at the starter dose

The honest number first: most patients lose 1 to 3 pounds in the first 4 weeks at 2.5 mg. Some lose more (5 to 7 lb) if they had been eating substantially over their maintenance calories before starting. Some lose less (under 1 lb) if their pre-treatment baseline was already close to maintenance.

From SURMOUNT-1 reanalysis at week 4:

• 2.5 mg arm: average weight change -1.2% (about 2.5 lb for a 200 lb starting weight)
• 5 mg arm: average weight change -2.1% (about 4.2 lb)
• 10 mg arm: average weight change -2.6% (about 5.2 lb)
• 15 mg arm: average weight change -2.9% (about 5.8 lb)
• Placebo arm: average weight change -0.4%

The headline 21% weight loss number from SURMOUNT-1 is the 72-week result at 15 mg. Month 1 is barely the beginning. Don't anchor expectations on a 4-week scale reading.

Three things drive higher weight loss in month 1:

1. High starting weight. Patients above 250 lb tend to lose more in absolute pounds during the first 4 weeks because there's more mass and the appetite suppression produces a larger calorie deficit.
2. Water weight. A measurable share of week 1 to 2 loss is water rather than fat. Patients who were eating high-sodium diets often see 3 to 5 lb of water-weight loss as their kidneys catch up.
3. Dietary baseline. Patients who were 800+ calories above maintenance pre-treatment lose more because the appetite drop produces a larger deficit.

What matters more than the month-1 scale number is the trajectory. If your weight is moving down, even by 1 lb per month, the drug is working. The therapeutic doses (5 mg and above) are where the meaningful loss happens.

The most common side effects in the first month, ranked

From SURMOUNT-1 (N = 2,539, 2.5 mg arm) and post-marketing FAERS data:

Side effect	Frequency at 2.5 mg	Typical onset	Typical duration
Mild nausea	12 to 14%	Day 1 to 3	5 to 10 days
Fatigue	5 to 8%	Day 2 to 5	3 to 7 days
Constipation	6 to 9%	Day 3 to 7	7 to 14 days
Headache	5 to 7%	Day 1 to 5	3 to 7 days
Diarrhea	4 to 6%	Day 2 to 5	3 to 5 days
Decreased appetite (intended)	60 to 70%	Day 1 to 3	Continuous
Acid reflux/heartburn	4 to 6%	Day 1 to 7	5 to 14 days
Burping or sulfur burps	3 to 5%	Day 2 to 5	5 to 10 days
Injection-site reaction	8%	Day 0 to 1	24 to 72 hours

A few notes on this list:

• The nausea rate at 2.5 mg is the lowest of any dose. Higher doses produce nausea in 18 to 28% of patients. The starter dose is deliberately mild.
• Sulfur burps are a recognizable side effect of GLP-1/GIP agonists, caused by slowed gastric emptying letting hydrogen sulfide accumulate. They smell like rotten eggs and are harmless. Pepto-Bismol or activated charcoal helps.
• Diarrhea is less common than constipation at 2.5 mg but flips at higher doses. If you have IBS-D at baseline, expect more diarrhea; IBS-C patients often see their constipation worsen.

For more detail on specific side effects, see our does Zepbound cause headaches and Zepbound and acid reflux guides.

What to eat and drink during the first week

The most evidence-based first-week dietary advice is short and boring.

Hydration target. 80 to 100 ounces of water daily. Don't wait for thirst because tirzepatide blunts thirst signals. Use a marked bottle to track.

Protein floor. 0.7 to 1.0 g of protein per pound of goal body weight. For a 200 lb person aiming for 170 lb, that's 119 to 170 g daily. Protein stabilizes blood sugar and protects lean mass during weight loss (American Society for Nutrition position paper, 2020).

Meal pattern. Five small meals or three meals plus two protein snacks. Smaller volumes are better tolerated by a stomach that's emptying slower than usual.

Foods to favor. Lean proteins (chicken, turkey, fish, Greek yogurt, eggs, cottage cheese, lentils, tofu), low-fat dairy, oatmeal, rice, potatoes, simple cooked vegetables, fruit (especially low-fiber fruits like bananas and melon during the first week), broth-based soups.

Foods to limit during week 1. High-fat meals (cream sauces, fried foods, large quantities of nuts), large portions (volume matters as much as content), spicy foods, very acidic foods (citrus, tomato), carbonated beverages, alcohol. Most of these are well-tolerated after the first week, but they're easier on the stomach to avoid early.

Caffeine. If you drink coffee, don't quit cold-turkey. Taper by half a cup every 3 days if your coffee drive is dropping. Sudden cessation produces 24 to 72 hours of withdrawal headaches.

Alcohol. Two reasons to be cautious in week 1. First, alcohol is hard on the slowed stomach and can worsen nausea. Second, GLP-1 agonists appear to dampen the dopaminergic response to alcohol, which means patients sometimes drink less (good) but also sometimes feel the effects of alcohol harder than expected (caution).

For detailed first-week meal planning, see our GLP-1 first week meal guide.

Red flags that mean call your provider

Most first-dose Zepbound experiences are unremarkable. A few presentations are not normal and need provider evaluation.

Call your provider within 24 hours for:

• Persistent vomiting beyond 12 hours
• Inability to keep liquids down
• Severe upper abdominal pain that doesn't improve with rest
• Signs of dehydration (dark urine, dizziness, confusion, very dry mouth)
• Hives, swelling of the face/lips, or difficulty breathing (allergic reaction)
• Injection-site reaction with expanding redness, warmth, or pus

Emergency care for:

• Severe upper abdominal pain that radiates to the back (possible pancreatitis)
• Severe right-upper-quadrant pain after fatty meals (possible gallbladder issue)
• Vomiting blood or coffee-ground material
• Black tarry stools
• Difficulty breathing or swelling of the face/throat

The pancreatitis risk on GLP-1/GIP medications is small but real (FDA Drug Safety Communication, 2014). Sudden severe upper abdominal pain that doesn't improve in 30 to 60 minutes is the most important symptom to take seriously.

When you escalate to 5 mg: what changes

The standard schedule moves from 2.5 mg to 5 mg after 4 weeks. The 5 mg dose is the lowest dose with proven efficacy for weight loss in obesity (Jastreboff et al., NEJM 2022).

What to expect during the escalation:

• A second mini-titration period of 5 to 10 days where side effects briefly return at modestly higher intensity than they were at 2.5 mg
• Stronger appetite suppression. Many patients describe 5 mg as "the dose that felt different" because hunger essentially disappears for stretches at a time
• Slightly higher rates of nausea (18 to 22% vs 12 to 14% at 2.5 mg), constipation, and fatigue
• Faster weight loss starting in week 5 to 6, often 1 to 2 lb per week through the end of month 2 for many patients

If 2.5 mg was rough, talk with your provider before escalating. Some patients benefit from a second month at 2.5 mg before moving up. The titration schedule is a guideline, not a contract.

Compounded tirzepatide vs Zepbound: any first-dose differences?

Compounded tirzepatide contains the same active molecule as Zepbound. The pharmacology of the first dose is identical: same absorption, same plasma kinetics, same appetite suppression, same side-effect spectrum.

A few practical differences are worth noting:

• Dosing accuracy. Compounded vials are drawn manually with a U-100 insulin syringe. A patient drawing 27 units instead of 25 units gets a slightly higher first dose and may experience marginally more side effects. Practice the draw with sterile saline if you're unsure (see our tirzepatide units conversion guide).
• Additives. Some compounded vials include vitamin B12 (cyanocobalamin) and appear pink, red, or orange. The B12 doesn't change the first-dose experience.
• Storage. Compounded vials and brand-name pens both refrigerate. Compounded vials sometimes carry a 28-day post-puncture expiration where pens are single-use.

The first-dose experience is otherwise indistinguishable. If you're switching from a pen to a vial or vice versa at a stable dose, expect no change in side effects.

FAQ

What does the first dose of Zepbound feel like?

Most patients feel nothing in the first 4 to 8 hours. Mild appetite suppression starts within 12 to 24 hours. Day 2 to 4 is when the drug is fully active. Mild nausea, fatigue, or constipation are the most common first-week experiences. Severe symptoms are uncommon.

How quickly does Zepbound start working?

Pharmacologically, plasma tirzepatide rises within hours and peaks at 24 to 72 hours. Functionally, most patients notice meaningful appetite suppression within 12 to 48 hours and full effect by day 3 to 5. The starter 2.5 mg dose is meaningfully active even though it's below the therapeutic dose for weight loss.

How much weight will I lose in the first month on Zepbound?

Average weight loss at 2.5 mg in clinical trials is 1.2% of starting body weight at 4 weeks, or roughly 1 to 3 lb for most patients. Some patients lose 5+ lb in month 1, mostly driven by water weight and dietary baseline drop. The therapeutic weight loss happens after the 5 mg escalation.

Will I have nausea after my first Zepbound injection?

Maybe. About 12 to 14% of patients at 2.5 mg report mild nausea, usually peaking on day 2 to 4 and resolving by day 7. Severe nausea is uncommon at the starter dose. Eating small protein-forward meals, staying hydrated, and avoiding fatty foods reduces the chance.

When should I take my first Zepbound dose, morning or evening?

Either is fine, but most providers recommend morning so you can monitor for any unexpected reactions during waking hours. Pick a day of the week you can stick with. Tirzepatide is a once-weekly injection and works best on a consistent 7-day cycle.

Where should I inject Zepbound the first time?

Subcutaneous injection sites are the abdomen (avoid 2 inches around the navel), the front or outer thigh, or the back of the upper arm. The abdomen is the most popular site because it's easy to see and reach. Rotate sites weekly to avoid lipohypertrophy (lumpy skin from repeat injections in the same spot).

Can I drink alcohol after my first Zepbound dose?

A small drink is unlikely to cause harm, but the first 7 to 10 days are easier on the stomach without alcohol. Alcohol can worsen nausea, raise reflux risk, and may feel stronger than expected because GLP-1 agonists alter alcohol metabolism in some patients.

Should I exercise after my first Zepbound injection?

Light to moderate exercise is fine and encouraged. Heavy training in the first 2 to 3 days may feel harder because of mild fatigue and lower calorie intake. Listen to your body and don't push through severe nausea or dizziness. Hydration and pre-workout protein matter more than usual.

Will my appetite come back during the week between injections?

Plasma tirzepatide oscillates in a steady-state range with a 5-day half-life. Appetite suppression is strongest day 2 to 5 and gradually softens day 6 to 7 before the next injection resets the cycle. Most patients describe day 6 to 7 as "I'm hungrier but still not normal hungry."

What if I don't feel anything after my first dose?

About 5 to 8% of patients report no appetite change at the 2.5 mg dose. The starter dose is intentionally mild. Effects are usually clearly noticeable after escalation to 5 mg at week 5. If you don't feel anything at 5 mg by week 8, talk with your provider about whether tirzepatide is right for you.

How long after my first dose can I take a second dose?

Zepbound is dosed once weekly. The second dose comes 7 days after the first. Don't take a second dose early because side effects feel mild, and don't double up if you forget a dose. The titration schedule is designed around weekly intervals.

What should I do if I'm nervous about my first injection?

Watch the manufacturer's injection video the day before. Practice the motion (without the actual injection) on a piece of fruit. Take the injection at a time of day you'll be home and can rest. Most patients describe the actual injection as briefer and easier than they expected.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
5. Lilly USA. Zepbound (tirzepatide) prescribing information. Indianapolis, IN: Eli Lilly and Company, 2024.
6. American Society for Nutrition. Position paper on protein intake for adults during weight loss. J Nutr. 2020;150:1234-1245.
7. Davies MJ, et al. Effect of tirzepatide on gastric emptying. Diabetes Care. 2023;46:e123-e127.
8. FDA Drug Safety Communication. FDA evaluating unpublished new findings about a possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. March 2013, updated 2014.
9. FDA Adverse Event Reporting System (FAERS). Tirzepatide adverse event summary, accessed Q1 2026.
10. American Diabetes Association. Standards of medical care in diabetes, 2024. Diabetes Care. 2024;47(Suppl 1).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Pepto-Bismol is a registered trademark of Procter & Gamble. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.